A Randomized Open-Label Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination with Immune Checkpoint Blockade for Patients with Colon Cancer with Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chem

Brief description of study

The purpose of the study is to determine the safety and effectiveness of the patient-specific-vaccine targeting neoantigens in combination with immune checkpoint blockade for patients with colon cancer. We will characterize the antitumor activity of adjuvant treatment with GRT-C901/GRT-R902 in combination with checkpoint inhibitors based on molecular response. The vaccine has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new agents to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s21-01701
ClinicalTrials.gov Identifier: NCT05456165
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.